Physician profile
Silpa Maram
NPI 1518189497
$4,301.02
in general payments reported to CMS, 2019-2025
34 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $560 · 2021: $921 · 2022: $761 · 2023: $517 · 2024: $391 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $793.44 | 2019-2025 | Repatha, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $595.37 | 2019-2022 | |
| Abbott Laboratories | $541.75 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $267.71 | 2019-2023 | |
| Glaxosmithkline, LLC. | $261.39 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $230.91 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $200.96 | 2019-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.98 | 2019-2021 | |
| Amarin Pharma, INC. | $138.50 | 2020-2022 | |
| Allergan, INC. | $133.16 | 2019-2020 | |
| Lilly USA, LLC | $106.67 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $102.29 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $81.91 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.53 | 2020-2023 | Xifaxan, Trulance |
| Novo Nordisk INC | $73.84 | 2019-2025 | Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66.74 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $63.90 | 2019-2022 | |
| Boston Scientific Corporation | $50.33 | 2019-2022 | |
| Nevro Corp. | $44.38 | 2022-2024 | Senza |
| Genentech USA, INC. | $39.27 | 2019-2021 | |
| Dexcom, INC. | $36.27 | 2023-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $33.32 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.07 | 2021 | |
| Merck Sharp & Dohme LLC | $27.13 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $25.72 | 2019-2021 | |
| Bardy Diagnostics, INC. | $20.00 | 2021 | |
| Astellas Pharma US INC | $15.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.74 | 2021 | |
| Nabriva Therapeutics, Plc | $15.24 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.36 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.18 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.17 | 2023 | Linzess |
| Eisai INC. | $12.93 | 2021 | |
| Phathom Pharmaceuticals, INC. | $2.88 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silpa Maram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.